Compare CELZ & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELZ | ASBP |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.8M |
| IPO Year | 2008 | N/A |
| Metric | CELZ | ASBP |
|---|---|---|
| Price | $1.07 | $5.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.1M | 210.2K |
| Earning Date | 05-08-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.79 | $0.05 |
| 52 Week High | $6.25 | $7.05 |
| Indicator | CELZ | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 31.32 | 50.35 |
| Support Level | $0.79 | $0.19 |
| Resistance Level | $2.33 | $6.98 |
| Average True Range (ATR) | 0.45 | 0.78 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 6.74 | 45.16 |
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.